N/A N=68 Targeted Levothyroxine Dosing in Infants With Congenital Hypothyroidism
Congenital Hypothyroidism
Primary: Dose Adjustments — 2.5; 2.4 Number of dose adjustments
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,203 Thyroid Therapy for Mild Thyroid Deficiency in Pregnancy
Subclinical Hypothyroidism · Hypothyroxinemia · Pregnancy
Primary: Intellectual Function of Children at 5 Years of Age in Women Diagnosed With a) Subclinical Hypothyroidism or b) Hypothyroxinemia During the First Half of Pregnancy, or…
N/A N=843 Observational Study on Hypothyroidism in Young Children Following Iodine Contrast Exposure
Hypothyroidism
Primary: Number of Pediatric Patients With Detected Hypothyroidism After Iodinated Contrast Exposure in a Routine Clinical Practice Setting — 11 Participants
N/A N=2,320 Iodinated Contrast Agents and Risk of Hypothyroidism in Young Children in the United States
Hypothyroidism
Primary: Incidence Rate of Hypothyroidism Detected in Routine Clinical Practice — 15.9 events per 1,000 person years
N/A N=12 Treatment Trial of Subclinical Hypothyroidism in Down Syndrome
Down Syndrome · Subclinical Hypothyroidism
Primary: Change in Lipid Panel From Baseline at 6, 12 and 18 Months. — 160; 170; 163; 172 mg/dL
Phase 3 N=175 Efficacy Assessment of Systematic Treatment With Folinic Acid and Thyroid Hormone on Psychomotor Development of Down Syndrome Young Children
Down Syndrome
Primary: GMDS (Griffiths Mental Development Scale) — 51.96; 51.27; 51.66; 51.67 developpement quotient
Phase 3 N=62 Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia
Congenital Adrenal Hyperplasia (CAH)
Primary: Adult Height Relative to General Population — -0.34; -0.6 Standard Deviation Score (SDS) units
Phase 4 N=20 Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia
Growth Hormone Deficiency · Septo-Optic Dysplasia · Hypopituitarism
Primary: Change in Anthropometric Measures Over Time — 1.97; -0.61; 1.39; 1.22 Z-score
Phase 4 N=11 Hypothyroidism Treated With Calcitonin
Hypothyroidism
Primary: Modified City of Hope Quality of Life Questionnaire for Patients With Thyroid Disease — -36.33 score on a scale
Phase 3 N=220 Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass
Congenital Heart Defects
Primary: Time To Extubation — 46.9; 48.0 hours — p=<.05
Phase 4 N=173 Neurocognitive and Metabolic Effects of Mild Hypothyroidism
Hypothyroidism
Primary: Executive Function — 7.9; 7.5; 8.8 units on a scale
Phase 3 N=24 Treatment of Adrenal Insufficiency in Children
Adrenal Insufficiency
Primary: Serum Cortisol Concentration up to 240 Minutes — 575.8 nmol/L
Phase 3 N=61 Early Levothyroxine Post Radioactive Iodine
Graves' Disease
Primary: Number of Participants With Overt Hypothyroidism — 11; 17 Participants — p=0.23
Phase 2 N=8 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crinecerfont) in Pediatric Participants With Congenital Adrenal Hyperplasia
CAH - Congenital Adrenal Hyperplasia
Primary: Percent Change From Baseline to Day 14 in Serum 17-OHP Concentrations (Morning Window Average) — -69.48 percent change
N/A N=48 Thyroid Hormone Dose Adjustment in Pregnancy
Pregnancy · Hypothyroidism
Primary: Proportion of Patients in Each Treatment Arm Euthyroid Through Gestation — 24; 21 participants
Phase 2 N=10 A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
Congenital Adrenal Hyperplasia
Primary: Number of Participants With Reduction of 17-hydroxyprogesterone to </= 2 Times the Upper Limit of Normal at Any Time Following 2 Weeks of Dosing With ATR-101 — 2…
N/A N=39 Early-onset Obesity and Cognitive Impairment in Children With Pseudohypoparathyroidism
Pseudohypoparathyroidism · Albright Hereditary Osteodystrophy
Primary: Intelligence Quotient — 85.9; 104.3; 103.2 units on a scale
N/A N=34 Generic vs. Name-Brand Levothyroxine
Congenital Hypothyroidism · Hypothyroidism
Primary: Thyroid Stimulating Hormone as Primary Endpoint Measured at Initiation of Study, After 8 Weeks of One Drug, and Then 8 Weeks After the Second Drug. — 2.455; 2.131…
Phase 3 N=122 Comparison of Chronocort® With Standard Glucocorticoid Therapy in Patients With Congenital Adrenal Hyperplasia
Congenital Adrenal Hyperplasia
Primary: Change From Baseline to 24 Weeks of the Mean of the 24-hour Standard Deviation Score (SDS) Profile for 17-OHP — -0.403; -0.172 Z-score — p==0.5521
Phase 2 N=5 CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism
Congenital Hyperinsulinism
Primary: Number of Subjects With Clinically Meaningful Reduction in Glucose Infusion Rate (Double-Blind) — 2; 0 Participants
N/A N=90 FGF-21 Levels and RMR in Children and Adolescents With Hashimoto's Thyroiditis (THYROMETABOL)
Hashimoto Disease
Primary: Fibroblast Growth Factor 21 (FGF-21) — 182.71; 217.36; 198.43 pg/mL
N/A N=17 Effect of Growth Hormone on Early Brain Development in Girls With Turner Syndrome
Turner Syndrome
Primary: Total Brain Volume — 18.22; 19.78 percentage change
Phase 3 N=146 A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
Growth Hormone Deficiency, Pediatric · Endocrine System Diseases · Hormone Deficiency
Primary: Number of Participants With Treatment-Emergent Adverse Events [Safety and Tolerability] — 83; 6; 1; 0 Participants
Phase 2 N=14 Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia
Congenital Adrenal Hyperplasia · 21-Hydroxylase Deficiency · Adrenogenital Syndrome
Primary: Chronocort vs. Cortef Cortisol Concentrations (AUC Over 24 Hours - Time Points 0,.5,1,1.5,2,3,4,5,6,7,8,10,10.5,11, 11.5,12,13,15,17,17.5,18,18.5,19,20,22,24 Post Dose)…
N/A N=442 Cerebrotendinous Xanthomatosis (CTX) Prevalence Study
Cerebrotendinous Xanthomatosis (CTX)
Primary: Number of Participants Who Had Positive Genetic Test Results — 4 Participants
Phase 3 N=43 Genotropin Treatment In Very Young Children Born Small For Gestational Age
Infant, Small for Gestational Age
Primary: Change From Baseline in Height Standard Deviation Score (SDS) at Month 24. — 1.63; 0.43 SDS — p=<0.001
Phase 2 N=19 Radioactive Iodide Therapy for Pediatric Graves' Disease
Graves' Disease
Primary: Dosimetry Studies
Phase 2 N=106 Utility of [F-18] fluoroDOPA for Neonatal Hyperinsulinism
Congenital Hyperinsulinism · Hyperinsulinism · Persistent Hyperinsulinemic Hypoglycemia of Infancy
Primary: The Accuracy of FDOPA PET to Identify Focal Forms of Hyperinsulinism — 40; 6; 3; 46 Participants
Phase 3 N=55 Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia
Congenital Adrenal Hyperplasia
Primary: Percentage of Participants Who Were Biochemical Responders at Week 28 — 40.0; 14.3 percentage of participants — p=0.0003
Phase 2 N=8 Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia
Adrenal Insufficiency · Excess Androgen · Congenital Adrenal Hyperplasia (CAH)
Primary: Number of Patients With 17-OHP Levels Equal or Below 1,200 ng/dL at 0700 — 0 Participants